A Cambridge biotech advances a fresh approach to slowing Parkinson's

A clinical trial evaluating a novel compound called MTX325 has reached a significant milestone, giving its first dose to a person with Parkinson's. Developed by Mission Therapeutics, a biotechnology company based in Cambridge, UK, the drug takes a completely fresh route. Instead of merely replacing lost dopamine or smoothing out daily symptoms, it aims to protect brain cells directly by restoring their natural waste disposal system. Inside our cells are tiny power stations called mitochondria, which generate the energy needed to keep everything running smoothly. In Parkinson's, these powerhouses often become exhausted, damaged, and worn out. A healthy cell routinely clears away broken mitochondria through a tidy recycling process known as mitophagy. When that housekeeping fails, faulty power units pile up, creating toxic stress that makes it difficult for vulnerable dopamine producing cells to survive. This is where MTX325 steps in. The therapy works by blocking an enzyme called USP30, which acts like an unwanted brake on the recycling process. By releasing that brake, the medicine encourages cells to clear out the worn components and refresh their energy supply. In laboratory studies, turning off this enzyme protected key brain cells and helped maintain healthy movement. Having successfully cleared initial safety checks in healthy volunteers, the study has expanded into its next stage. Researchers across the UK, Europe, and Australia are now recruiting 36 individuals with mild to moderate Parkinson's. This phase will carefully assess how well the oral treatment is tolerated and confirm whether it triggers the expected cellular cleanup in the human body. The trial will run over the next couple of years, with initial findings expected towards late 2027. While it is still early days, targeting the underlying health of brain cells rather than just managing symptoms marks an encouraging step towards treatments that could one day alter the course of Parkinson's.